BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia
BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia
Shots:
- BioMarin has submitted an NDA to the US FDA for vosoritide to treat children with achondroplasia
- The company also reported that EMA has begun validation of MAA for the therapy on 13 Aug, 2020
- Vosoritide is an investigational, once-daily injection analog of C-type Natriuretic Peptide (CNP) and is potentially the first treatment for achondroplasia in the US
Click here to read full press release/ article | Ref: Biomarin | Image: Fierce Biotech